Biological Assembly 1  

 3D View: Structure | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Cyclic - C4  (3D View)
Global Stoichiometry: Homo 4-mer - A4 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 14315.77 
• Atom Count: 1010 
• Residue Count: 124 
• Unique protein chains: 1

2MUV

NOE-based model of the influenza A virus M2 (19-49) bound to drug 11

• DOI: 10.2210/pdb2MUV/pdb
• BMRB: 25233

• Classification: VIRAL PROTEIN
• Organism(s): Influenza A virus


• Deposited: 2014-09-18 Released: 2014-12-24 
• Deposition Author(s): Wu, Y., Wang, J., DeGrado, W.

---

Experimental Data Snapshot

• Method: SOLUTION NMR
• Conformers Calculated: 100 
• Conformers Submitted: 20 
• Selection Criteria: structures with the lowest energy 

Literature

Flipping in the Pore: Discovery of Dual Inhibitors That Bind in Different Orientations to the Wild-Type versus the Amantadine-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel.

Wu, Y., Canturk, B., Jo, H., Ma, C., Gianti, E., Klein, M.L., Pinto, L.H., Lamb, R.A., Fiorin, G., Wang, J., DeGrado, W.F.

(2014) J.Am.Chem.Soc. 136: 17987-17995

• PubMed: 25470189 
• DOI: 10.1021/ja508461m
• Primary Citation of Related Structures:  
  2MUW


• PubMed Abstract: 
  

Influenza virus infections lead to numerous deaths and millions of hospitalizations each year. One challenge facing anti-influenza drug development is the heterogeneity of the circulating influenza viruses, which comprise several strains with variable susceptibility to antiviral drugs. For example, the wild-type (WT) influenza A viruses, such as the seasonal H1N1, tend to be sensitive to antiviral drugs, amantadine and rimantadine, while the S31N mutant viruses, such as the pandemic 2009 H1N1 (H1N1pdm09) and seasonal H3N2, are resistant to this class of drugs. Thus, drugs targeting both WT and the S31N mutant are highly desired. We report our design of a novel class of dual inhibitors along with their ion channel blockage and antiviral activities. The potency of the most active compound 11 in inhibiting WT and the S31N mutant influenza viruses is comparable with that of amantadine in inhibiting WT influenza virus. Solution NMR studies and molecular dynamics (MD) simulations of drug-M2 interactions supported our design hypothesis: namely, the dual inhibitor binds in the WT M2 channel with an aromatic group facing down toward the C-terminus, while the same drug binds in the S31N M2 channel with its aromatic group facing up toward the N-terminus. The flip-flop mode of drug binding correlates with the structure-activity relationship (SAR) and has paved the way for the next round of rational design of broad-spectrum antiviral drugs.

---

Organizational Affiliation: 

Department of Pharmaceutical Chemistry, University of California , Mission Bay Box 3122, San Francisco, California 94158, United States.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Matrix protein 2	A, B, C, D	31	Influenza A virus	Mutation(s): 0  Gene Names: M2
Find proteins for B0LX40 (Influenza A virus) Go to UniProtKB:  B0LX40

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
3LW	C	(3s,5s,7s)-N-[(5-bromothiophen-2-yl)methyl]tricyclo[3.3.1.1~3,7~]decan-1-aminium C15 H21 Br N S IEDXEJPASCHMKZ-WUQLGEGHSA-O

Experimental Data & Validation

Experimental Data

• Method: SOLUTION NMR
• Conformers Calculated: 100 
• Conformers Submitted: 20 
• Selection Criteria: structures with the lowest energy 

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2014-09-18 
• Released Date: 2014-12-24 
• Deposition Author(s): Wu, Y., Wang, J., DeGrado, W.

Revision History 

• Version 1.0: 2014-12-24
  Type: Initial release
• Version 1.1: 2015-01-14
  Type: Database references